Brown Rudnick Represents Edwards Lifesciences in Strategic Transaction with Corvia Medical

Brown Rudnick represented Edwards Lifesciences, the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring, in a strategic transaction with Corvia Medical, Inc. 

Edwards invested $35 million in an exclusive right to acquire Corvia Medical, the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction. The Brown Rudnick team was led by partners Rob Funsten and Katy Gardner and included associates and Harrison Freeman. Support for the transaction was provided by partners Vince Guglielmotti and Nicole Bouchard (tax/employee benefits) as well as attorneys from our Intellectual Property Practice Group.